GBS (GBS) on Friday filed a shelf registration statement for the potential sale of up to $100 million of its securities from time to time.
The filing covers the sale of the company's common stock, preferred stock, debt securities, warrants, and units.
The company expects to use the net proceeds from the sale of securities for its clinical trials and preclinical programs, for other research and development activities and for general corporate purposes. These may include additions to working capital and acquisitions.
The filing covers the sale of the company's common stock, preferred stock, debt securities, warrants, and units.
The company expects to use the net proceeds from the sale of securities for its clinical trials and preclinical programs, for other research and development activities and for general corporate purposes. These may include additions to working capital and acquisitions.